Basic Information
| LncRNA/CircRNA Name | SNHG5 |
| Synonyms | NA |
| Region | GRCh38_6:85660950-85678736 |
| Ensemble | ENSG00000203875 |
| Refseq | NR_003038 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | hepatocellular carcinoma tissue, cell lines (Hep3B, HepG2, SMCC-7721, MHCC-97L, MHCC-97H, Huh7, LO2) |
| Expression Pattern | up-regulated |
| Function Description | SNHG5 was up-regulated in both HCC tissues and hepatoma cell lines. Knockdown of SNHG5 induced apoptosis and repressed cell cycle progression, cell growth, and metastasis in hepatoma cell lines, SNHG5 may act as a competing endogenous RNA by competitively binding miR-26a-5p. SNHG5 promotes tumor growth and metastasis by activating Wnt/?-catenin pathway and inducing epithelial to mesenchymal transition (EMT). SNHG5 knockdown caused a decrease in theclonogenic survival of HepG2 and MHCC-97L cellscompared with negative control. patients with high SNHG5 expression have shorter OSand higher recurrence rates than those with low SNHG5 expression. |
| Pubmed ID | 30166525 |
| Year | 2018 |
| Title | Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3? signal pathway. |
External Links
| Links for SNHG5 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |